ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics

ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics

Bewaard in:

Bibliografische gegevens
Hoofdauteurs:	Carlos L. Arteaga, Jeffrey A. Engelman
Formaat:	Revisão
Taal:	Engels
Gepubliceerd in:	2014
Online toegang:	https://doi.org/10.1016/j.ccr.2014.02.025 https://www.cell.com/article/S1535610814000865/pdf
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items

ERBB receptors: From oncogene discovery to basic science to mechanism-based cancer therapeutics
door: Arteaga, Carlos L., et al.
Gepubliceerd in: (2014)

ERBB receptors in cancer: signaling from the inside
door: Arteaga, Carlos L
Gepubliceerd in: (2011)

Human Breast Cancer Cells Selected for Resistance to Trastuzumab <i>In vivo</i> Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network
door: Christoph A. Ritter, et al.
Gepubliceerd in: (2007)

ErbB receptors: from oncogenes to targeted cancer therapies
door: Zhang, Hongtao, et al.
Gepubliceerd in: (2007)

ErbB receptors: from oncogenes to targeted cancer therapies
door: Hongtao Zhang, et al.
Gepubliceerd in: (2007)

When Tumor Suppressor TGFβ Meets the HER2 (ERBB2) Oncogene
door: Chow, Amy, et al.
Gepubliceerd in: (2011)

When Tumor Suppressor TGFβ Meets the HER2 (ERBB2) Oncogene
door: Amy Chow, et al.
Gepubliceerd in: (2011)

TWEAK/Fn14 Axis-Targeted Therapeutics: Moving Basic Science Discoveries to the Clinic
door: Cheng, Emily, et al.
Gepubliceerd in: (2013)

TWEAK/Fn14 Axis-Targeted Therapeutics: Moving Basic Science Discoveries to the Clinic
door: Emily H. Cheng, et al.
Gepubliceerd in: (2013)

MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors
door: Turke, Alexa B., et al.
Gepubliceerd in: (2012)

MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors
door: Alexa B. Turke, et al.
Gepubliceerd in: (2012)

Oncogenic ERBB3 Mutations in Human Cancers
door: Bijay S. Jaiswal, et al.
Gepubliceerd in: (2013)

Huntington's disease: From basic science to therapeutics
door: Cepeda, Carlos, et al.
Gepubliceerd in: (2018)

Molecular Mechanisms of Cardiotoxicity Induced by ErbB Receptor Inhibitor Cancer Therapeutics
door: Hervent, Anne-Sophie, et al.
Gepubliceerd in: (2012)

Molecular Mechanisms of Cardiotoxicity Induced by ErbB Receptor Inhibitor Cancer Therapeutics
door: Anne-Sophie Hervent, et al.
Gepubliceerd in: (2012)

Translating basic science discoveries into improved outcomes for glioblastoma
door: Dirks, Peter, et al.
Gepubliceerd in: (2020)

Mechanisms of resistance to ErbB-targeted cancer therapeutics
door: Wang, Qiang, et al.
Gepubliceerd in: (2008)

On the right TRK: from oncogene discovery to cancer therapeutics
door: Barbacid, M
Gepubliceerd in: (2019)

ErbB2 Is Necessary for ErbB4 Ligands to Stimulate Oncogenic Activities in Models of Human Breast Cancer
door: Mill, Christopher P., et al.
Gepubliceerd in: (2011)

FAK signaling is critical for ErbB-2/ErbB-3 receptor cooperation for oncogenic transformation and invasion
door: Benlimame, Naciba, et al.
Gepubliceerd in: (2005)

FAK signaling is critical for ErbB-2/ErbB-3 receptor cooperation for oncogenic transformation and invasion
door: Naciba Benlimame, et al.
Gepubliceerd in: (2005)

The Meniscus: Basic Science and Therapeutic Approaches
door: Nikodem Kuczyński, et al.
Gepubliceerd in: (2025)

ERBB1 and ERBB2 have distinct functions in tumor cell invasion and intravasation
door: Kedrin, Dmitriy, et al.
Gepubliceerd in: (2009)

Gastric Cancer Cell Glycosylation as a Modulator of the ErbB2 Oncogenic Receptor
door: Duarte, Henrique O., et al.
Gepubliceerd in: (2017)

PCSK9: From Basic Science Discoveries to Clinical Trials
door: Shapiro, Michael D., et al.
Gepubliceerd in: (2018)

The Spectrum of Fundamental Basic Science Discoveries Contributing to Organismal Aging
door: Farr, Joshua N, et al.
Gepubliceerd in: (2018)

The Spectrum of Fundamental Basic Science Discoveries Contributing to Organismal Aging
door: Joshua N. Farr, et al.
Gepubliceerd in: (2018)

Amplification of c‐erbB2 oncogene
door: Alessandro D. Santin, et al.
Gepubliceerd in: (2005)

Amplification and overexpression of the EGF receptor and c-erbB-2 proto-oncogenes in human stomach cancer
door: NR Lemoine, et al.
Gepubliceerd in: (1991)

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation
door: Holbro, Thomas, et al.
Gepubliceerd in: (2003)

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation
door: Thomas Holbro, et al.
Gepubliceerd in: (2003)

The Role of the ErbB Family Members in Non–Small Cell Lung Cancers Sensitive to Epidermal Growth Factor Receptor Kinase Inhibitors
door: Jeffrey A. Engelman, et al.
Gepubliceerd in: (2006)

High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints
door: Lisio, Michael-Antony, et al.
Gepubliceerd in: (2019)

High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints
door: Michael-Antony Lisio, et al.
Gepubliceerd in: (2019)

ERBB2 oncogenicity: ERBIN helps to perform the job
door: Mei, Lin, et al.
Gepubliceerd in: (2015)

Synergy between the erbB and transforming growth factor beta signaling networks: implications for molecular therapeutics in human neoplasia
door: Arteaga, CL
Gepubliceerd in: (2003)

Amplification and overexpression of the EGF receptor and c-erbB-2 proto-oncogenes in human stomach cancer.
door: Lemoine, N. R., et al.
Gepubliceerd in: (1991)

Expression of oncogenes in thyroid tumours: coexpression of c-erbB2/neu and c-erbB.
door: Aasland, R., et al.
Gepubliceerd in: (1988)

Expression of oncogenes in thyroid tumours: coexpression of c-erbB2/neu and c-erbB
door: Rein Aasland, et al.
Gepubliceerd in: (1988)

Oncogenic Signalling of Growth Factor Receptors in Cancer: Mechanisms and Therapeutic Opportunities
door: Dricu, Anica
Gepubliceerd in: (2022)